Companies › Lakefront Biotherapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jul 2039.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GLPG CAR T-cell therapy Chimeric antigen receptor (CAR) T-cell therapy | – | Phase 3 | Hematological Malignancies | Jul 2039 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06652633 | GLPG CAR T-cell therapy | Phase 3 | Hematological Malignancies | Oncology | Jul 2039 |
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
GT Medical Technologies Suzhou Immunofoco Biotechnology Biofrontera CG Oncology CNBG-Virogin Biotech (Shanghai)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.